Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial

Immunologic Research

Volumn 65, Issue 4, 2017, Pages 969-974

  Shao, Nan ^a   Jia, Huixin ^a   Li, Yiwen ^b   Li, Jingying ^a  

^a Daqing Oil Field General Hospital   (China)

^b Meitan General Hospital   (China)

Author keywords

Birmingham Vascular Activity Score; C reactive protein; Curcumin; Takayasu arteritis; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; CURCUMIN; PLACEBO; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; AORTIC ARCH SYNDROME; ARTICLE; BIRMINGHAM VASCULAR ACTIVITY SCORE; CARDIOVASCULAR DISEASE ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CHINA; METABOLISM; MIDDLE AGED; PLACEBO EFFECT; YOUNG ADULT;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHINA; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; TAKAYASU ARTERITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85016124933     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-017-8917-z     Document Type: Article

References (41)

1. Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J. 2013;77:477–83.
2. Kallappa Parameshwarappa S, Mandjiny N, Kavumkal Rajagopalan B, Radhakrishnan N, Samavedam S, Unnikrishnan M. Intact giant abdominal aortic aneurysm due to Takayasu arteritis. Ann Vasc Surg. 2013;27:671 e11–4. doi:10.1016/j.avsg.2012.06.022.
3. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64:1079–83. doi:10.1002/acr.21636.
4. Nasu T. Takayasu’s truncoarteritis in Japan. A statistical observation of 76 autopsy cases. Pathol Microbiol (Basel). 1975;43:140–6.
5. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56:1000–9. doi:10.1002/art.22404.
6. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin N Am. 2007;33:777–86. vi doi:10.1016/j.rdc.2007.07.014.
7. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005;34:34–8. doi:10.1016/j.semarthrit.2005.01.009.
8. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–304. doi:10.1002/art.20300.
9. Tato F, Rieger J, Hoffmann U. Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol. 2005;24:304–7.
10. Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med. 2006;45:313–6.
11. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67:1567–9. doi:10.1136/ard.2008.093260.
12. Maffei S, Di Renzo M, Santoro S, Puccetti L, Pasqui AL. Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci. 2009;13:63–5.
13. Nunes G, Neves FS, Melo FM, de Castro GR, Zimmermann AF, Pereira IA. Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol. 2010;50:291–8.
14. Buonuomo PS, Bracaglia C, Campana A, Insalaco A, Pardeo M, Cortis E, et al. Infliximab therapy in pediatric Takayasu’s arteritis: report of two cases. Rheumatol Int. 2011;31:93–5. doi:10.1007/s00296-009-1147-5.
15. Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014;559:91–9. doi:10.1016/j.abb.2014.06.006.
16. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008;9:243–50.
17. Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J. Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int Immunopharmacol. 2010;10:815–8. doi:10.1016/j.intimp.2010.04.021.
18. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig. 2011;29:208–13. doi:10.3109/07357907.2010.550592.
19. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–34.
20. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671–8.
21. Nooshin D, Neda P, Shahdokht S, Ali J. Ten-year investigation of clinical, laboratory and radiologic manifestations and complications in patients with Takayasu’s arteritis in three university hospitals. Malays J Med Sci. 2013;20:44–50.
22. Minciullo PL, Catalano A, Mandraffino G, Casciaro M, Crucitti A, Maltese G, et al. Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Exp. 2016;64:111–26. doi:10.1007/s00005-015-0377-3.
23. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clin. 2015;3:280–8. doi:10.1016/j.bbacli.2015.04.001.
24. Cheng X, Wang Q, Li N, Zhao H. Effects of resveratrol on hippocampal astrocytes and expression of TNF-alpha in Alzheimer’s disease model rate. Wei Sheng Yan Jiu. 2015;44:610–4.
25. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45:545–8. doi:10.1093/rheumatology/kei266.
26. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu’s arteritis. Clin Immunol. 2006;118:154–8. doi:10.1016/j.clim.2005.09.010.
27. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, et al. Anti TNF-alpha in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev. 2012;11:678–84. doi:10.1016/j.autrev.2011.11.025.
28. Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu’s arteritis treated with infliximab. Clin Exp Rheumatol. 2012;30:922–8.
29. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270:24995–5000.
30. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res. 1999;39:41–7. doi:10.1006/phrs.1998.0404.
31. Jang MK, Sohn DH, Ryu JH. A curcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria. Planta Med. 2001;67:550–2. doi:10.1055/s-2001-16482.
32. Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, et al. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol. 2004;68:51–61. doi:10.1016/j.bcp.2004.03.015.
33. Jin CY, Lee JD, Park C, Choi YH, Kim GY. Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin. 2007;28:1645–51. doi:10.1111/j.1745-7254.2007.00651.x.
34. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 2007;80:926–31. doi:10.1016/j.lfs.2006.11.030.
35. Cretu E, Trifan A, Vasincu A, Miron A. Plant-derived anticancer agents—curcumin in cancer prevention and treatment. Rev Med Chir Soc Med Nat Iasi. 2012;116:1223–9.
36. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol. 2003;284:G321–7. doi:10.1152/ajpgi.00230.2002.
37. El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SF, Ahmed AF. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-alpha and free fatty acids. Food Chem Toxicol. 2011;49:1129–40. doi:10.1016/j.fct.2011.02.004.
38. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med. 2006;34:1874–82. doi:10.1097/01.CCM.0000221921.71300.BF.
39. Leyon PV, Kuttan G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumour specific angiogenesis. J Exp Clin Cancer Res. 2003;22:77–83.
40. Nishida M, Nishiumi S, Mizushina Y, Fujishima Y, Yamamoto K, Masuda A, et al. Monoacetylcurcumin strongly regulates inflammatory responses through inhibition of NF-kappaB activation. Int J Mol Med. 2010;25:761–7.
41. Huang WT, Niu KC, Chang CK, Lin MT, Chang CP. Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol. 2008;593:105–11. doi:10.1016/j.ejphar.2008.07.017.